All In Biotech

Drug Trial Radar · NCT04315948

Trial of Treatments for COVID-19 in Hospitalized Adults

Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,552 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,552

Actual

Start

Mar 22, 2020

Primary completion

Jul 9, 2022

Study completion Sep 25, 2023

Sponsor

Sponsor type
Government (non-federal)
First posted
Mar 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DisCoVeRy is a randomized controlled trial among adults (≥18-year-old) hospitalized for COVID-19. This study is an adaptive, randomized, open or blinded, depending on the drug to be evaluated, clinical trial to evaluate the safety and efficacy of possible therapeutic agents in hospitalized adult patients diagnosed with COVID-19. The study is a multi-centre/country trial that will be conducted in various sites in Europe with Inserm as sponsor. The study will compare different investigational therapeutic agents to a control group managed with the SoC including corticosteroids and anticoagulants. There will be interim monitoring to allow early stopping for safety and to introduce new therapies as they become available. If one therapy proves to be superior to others in the trial, this treatment may become part of the SoC for comparison(s) with new experimental treatment(s). In previous versions of the DisCoVeRy protocol, remdesivir, lopinavir/ritonavir with or without interferon ß-1a and hydroxychloroquine were evaluated as potential treatments for COVID-19. These treatments have been discontinued based on analyses review by both DSMC/DSMB, the Solidarity Executive Group and the DisCoVeRy steering committee. This version of the protocol, therefore, describes a randomized blinded placebo-controlled trial among adults (≥18-year-old) hospitalized for COVID-19 that randomly allocates them (1:1 ratio) between 2 arms: SoC + placebo versus SoC + AZD7442. Randomization will be stratified by region (according to the administrative definition in each country), antigenic status (positive or negative) obtained from the result of a rapid antigen test on nasopharyngeal swab performed at enrolment and vaccination initiation (yes or no). The primary analyses will be conducted on patients with antigen-positive results. A positive antigenic test is evidence of high viral shedding consistent with a recently started or uncontrolled infection. Overall, the number of antigen-negative patients will be at most 30% of all included subjects. The number of patients with vaccination (partly or fully) will be limited to 20% of all participants, split evenly between antigen positive and antigen negative patients (i.e. vaccinated patients can make up at most 20% of antigene positive patients and 20% of antigene negative patients). Sensitivity analyses will be performed in all patients, stratified by antigenic status and vaccination initiation. A global independent data and safety monitoring board (DSMB) monitors interim data to make recommendations about early study closure or changes to conduct, including adding or removing treatment arms. However, the current version of the protocol does not allow for efficacy or futility analysis, and the ability to add trial arms will be limited by the study being blinded and placebo-controlled during the investigation of AZD7442.

Conditions

  • Corona Virus Infection

Interventions

  • RemdesivirDrug

    The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.

  • Lopinavir/ritonavirDrug

    The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the "a" logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).

  • Interferon Beta-1ADrug

    IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.

  • HydroxychloroquineDrug

    Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).

  • Standard of careOther

    Standard of care

  • AZD7442Drug

    AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.

  • PlaceboOther

    Since April, 2021, the placebo will be a 0.9% (w/v) NaCl solution for infusion also called saline. The placebo will be supplied as a single 10-mL, clear and colorless vial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects reporting each severity rating on a 7-point ordinal scaleTime frame: Day 15

Locations

62 sites in 7 countries. Site status is shown where the registry gives one.

  • Medizinische Universität Innsbruck

    Innsbruck, Austria

  • Kepler Universitätsklinikum Linz

    Linz, Austria

  • Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität

    Salzburg, Austria

  • Hôpital Erasme - Cliniques universitaires de Bruxelles

    Brussels, Belgium

  • Hôpital Saint Luc

    Brussels, Belgium

  • Hôpital La Citadelle

    Liège, Belgium

  • Pôle Hospitalier Jolimont / site de Mons-Warquignies

    Mons, Belgium

  • Centre Hospitalier Universitaire Amiens-Picardie

    Amiens, France

  • Centre Hospitalier Regional Metz-Thionville

    Ars-Laquenexy, France

  • Centre Hospitalier Régional Universitaire de Besançon

    Besançon, France

  • Centre Hospitalier Universitaire de Bordeaux

    Bordeaux, France

  • CHU APHP Ambroise-Paré

    Boulogne-Billancourt, France

  • Centre Hospitalier Andrée Rosemon

    Cayenne, France

  • Hospices Civil

    Colmar, France

  • APHP - hôpital Henri-Mondor

    Créteil, France

  • Centre Hospitalier Universitaire Dijon-Bourgogne

    Dijon, France

  • Centre Hospitalier Annecy Genevois

    Épagny, France

  • Centre Hospitalier Universitaire de Martinique

    Fort de France, France

  • Centre Hospitalo-Universitaire de Grenoble

    La Tronche, France

  • AP-HP Hôpital Bicêtre

    Le Kremlin-Bicêtre, France

  • Centre Hospitalier Régional Universitaire de Lille

    Lille, France

  • Hospices Civils de Lyon

    Lyon, France

  • Centre Hospitalier Universitaire de Montpellier

    Montpellier, France

  • Groupe Hospitalier de la Région de Mulhouse Sud Alsace

    Mulhouse, France

  • Centre Hospitalier Régional et Universitaire de Nancy

    Nancy, France

  • Centre Hospitalier Universitaire de Nantes

    Nantes, France

  • Centre Hospitalo-Universitaire de Nice

    Nice, France

  • CHU Nîmes

    Nîmes, France

  • APHP - Hôpital Lariboisière

    Paris, France

  • APHP - Hôpital Saint Louis

    Paris, France

  • APHP - Hôpital Saint Antoine

    Paris, France

  • APHP - Hôpital Universitaire Pitié Salpêtrière

    Paris, France

  • APHP - Hôpital Cochin

    Paris, France

  • Hôpital Paris Saint-Joseph et Marie Lannelongue

    Paris, France

  • APHP - Hôpital Necker

    Paris, France

  • APHP- Hôpital Européen Georges-Pompidou

    Paris, France

  • APHP - Hôpital Bichat Claude Bernard

    Paris, France

  • APHP - Hôpital Tenon

    Paris, France

  • CHU Poitiers

    Poitiers, France

  • CH Cornouaille

    Quimper, France

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.